Posts filtered by tags: Novartis[x]


To Make More Covid-19 Vaccines, Rival Drugmakers Team Up

Sanofi and Novartis are among the big pharmaceutical companies that have agreed to help make a competitor’s shots.
Tags: Novartis, Sanofi

The coronavirus variant found in South Africa has been detected in a New York resident for the first time. 10 states have reported cases so far.

New York Gov. Andrew Cuomo. Lev Radin/Pacific Press/LightRocket via Getty The coronavirus variant first found in South Africa has been detected in a New York resident, Gov. Cuomo said Sunday. The variant, called B.1.351, has spread to 36 countries, and 10 states in the US. The variant from South Africa may be able to evade vaccines, studies suggest. Visit the Business section of Insider for more stories. The coronavirus variant found in South Africa has been confirmed in a New York residen...
Tags: Health, New York, Texas, Science, California, Cdc, New York City, US, Trends, South Africa, Connecticut, Healthcare, Astrazeneca, Novartis, Pfizer, Nassau County

Pfizer-BioNTech's COVID-19 vaccine produces a much weaker immune response against the variant found in South Africa, a new study suggests

Margaret Keenan, 90, the first patient in the United Kingdom to receive the Pfizer/BioNtech covid-19 vaccine, speaks with Healthcare assistant Lorraine Hill as she prepares to leave University Hospital Coventry & Warwickshire, the day after receiving the first of two doses of the vaccine, on December 9, 2020 in Coventry, United Kingdom. The UK is the first country in the world to start vaccinating people with the Pfizer/BioNTech jab. Jonny Weeks/The Guardian - Pool/Getty Images Pfizer-BioN...
Tags: Health, UK, Science, Israel, US, Trends, South Africa, United Kingdom, Healthcare, Astrazeneca, Novartis, Pfizer, Vaccine, Reuters, Johnson Johnson, Shi

Cathie Wood's Ark Invest was busy in drug stocks this week. A review of what she bought and sold:

Between Monday and Thursday, Ark Innovation bought shares of Novartis and Regeneron Therapeutics.
Tags: Novartis, Cathie Wood

Meet 22 women who launched and led startups to an IPO, an accomplishment few female founders have ever reached

BlackLine Founder and CEO Therese Tucker. Courtesy of BlackLine, Inc. Very few women founders have been able to scale and lead their startups to an IPO.  Only about 4 accomplished this in 2020. Only about 20 have in recent history.  These trailblazing women come from a range of industries, from biomedicine to retail. When Bumble goes public this week, Whitney Wolfe Herd will be the youngest at 31.  Visit Insider's homepage for more stories. The odds are stacked against women in business. B...
Tags: Google, Startups, Leadership, Finance, Ipo, Women, Global, US, Trends, Strategy, Features, Michigan, Novartis, IAC, Public, New York Stock Exchange

RetinAI collaborates with Novartis to provide AI solutions for ophthalmology projects

RetinAI Medical AG announces a multi-year collaboration with Novartis Pharma AG under which RetinAI’s IT solutions and artificial intelligence tools shall be employed to support multiple projects in ophthalmology and digital health. Both companies have previously worked successfully on pilot projects in this disease area.
Tags: Health, Novartis, Novartis Pharma AG, RetinAI Medical AG

Working parents are reaching their 'breaking point' due to the pandemic, and they say national paid parental leave can't come soon enough

Samantha Lee/Business Insider Seventy-eight percent of Americans believe that working parents should be given paid leave to care for their children during the pandemic, a new survey finds. Getty Parents, particularly working mothers, are struggling during the coronavirus pandemic.  Juggling the responsibilities of work with the challenges of childcare has left many feeling burned out, and has caused some women to exit the workforce. There is currently no federally mandated paid p...
Tags: Microsoft, Congress, Colorado, Washington, US, Trends, House, Novartis, Business Insider, Jacobs, Allen, Center for American Progress, Steny Hoyer, Barnard College, Carolyn Maloney, Don Beyer

What to know about Trump's coronavirus treatment regimen

Hollis Johnson/Business Insider Hello,What a weekend. Since being diagnosed with COVID-19 on Thursday, President Donald Trump has received a number of treatments. Those include an experimental antibody therapeutic from drugmaker Regeneron and the antiviral remdesivir.On Sunday, White House physician Sean Conley said that Trump was feeling better, but noted that the president had received dexamethasone, a steroid usually reserved for patients with more serious cases, Aylin Woodward reported...
Tags: Politics, Microsoft, White House, US, Trends, Healthcare, Novartis, Oxygen, Donald Trump, Walter Reed, Trump, Bristol Myers, Regeneron, Mark Meadows, Walter Reed National Military Medical Center, Hollis Johnson

While the world is gripped by COVID-19, another devastating health threat is building — this one from bacteria

As bacteria becomes more resistant, the spread of disease is slowly growing to become a pandemic-level threat. Samantha Lee/Business Insider While the world focuses on defeating the coronavirus, less attention has been paid to another global threat: bacterial disease. Infections from bacteria are on a slow march to become a COVID-19-level threat, experts told Insider, and growing antibiotic resistance means there are few ways to stop it. The spread of the coronavirus, they said, shows how ...
Tags: Science, News, Cdc, US, Trends, Bacteria, NHS, Harvard University, United Kingdom, Healthcare, National Health Service, Disease, Who, World Health Organization, National Institutes of Health, Novartis

PadSquad Deploys the Iguazio Data Science Platform to Predict Ad Performance in Real-Time

PadSquad uses Iguazio to deliver high-performing interactive campaigns served in real-time for Fortune 500 brands including Intel, Verizon and Novartis. The company analyzes behavioral data from multiple sources in order to serve the right ad creative to the right customer at the right moment. Iguazio selected for ease of AI deployment and ability to bring […] The post appeared first on Ad Tech Daily.
Tags: Advertising, Data Science, Press Releases, Novartis, Ad & Media Strategies, Digital Intelligence, Ad Products, Padsquad, Intel Verizon, Iguazio, Ad Performance, Iguazio Data Science Platform

Bio Roundup: Grail Acquisition, Libra’s Launch, Tau Trial Results & More

In biotech, you can go home again. Four years ago, Illumina spun out cancer diagnostics startup Grail. This week, the gene sequencing giant announced it is acquiring Grail in an $8 billion cash and stock deal.Grail set out with the goal of developing a diagnostic test that detects cancer from the genetic snippets tumors shed into the blood. The idea is to diagnose cancer well before symptoms show, giving clinicians a better chance to treat the disease. Grail has tested its technology in tens of...
Tags: Deals, Startups, Trends, Alzheimer's Disease, Fda, National, Novartis, Biotech, Microbiome, Morningside Ventures, Illumina, Life Sciences, Liquid Biopsy, Clinical Trials, Roche, ARCH Venture Partners

Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More

Gilead Sciences CEO Daniel O’Day has spoken openly about acquisitions as a way to build up the company’s drug pipeline. This week, it made its biggest buy yet.The $21 billion Immunomedics acquisition brings to Gilead a cancer drug that many analysts project will become a blockbuster seller. Some of those analysts think Gilead might have overpaid but the company says there were competing offers. The drug, sacitizumab govitecan (Trodelvy), is what’s called an antibody drug conjugate (ADC). This d...
Tags: Deals, Startups, Cancer, Hiv, Trends, Merck, Alzheimer's Disease, Astrazeneca, Fda, National, Novartis, Pfizer, Abbvie, Biotech, Medical Device, Microbiome

Roche jumps 2% after unveiling COVID-19 antibody test, and on finding its drugs cut need for ventilators

Roche tablets are seen positioned in front of a displayed Roche logo in this photo illustration. Reuters Shares in Swiss healthcare group Roche rose 2% on Friday after the company launched a new test to measure COVID-19 antibodies, and provided evidence its drugs reduce need for ventilators.The new measure is Roche's 12th test in its coronavirus portfolio. The company has filed for emergency-use authorization from the US Food and Drug Administration.In a separate study, the healthcare firm ...
Tags: Mexico, US, Trends, Goldman Sachs, Novartis, Roche, US Food and Drug Administration, Reuters Shares, Roche Diagnostics, Thomas Schinecker, Shalini Nagarajan, US South Africa Brazil, Levi Garraway Roche

Grifols Moves Deeper Into Proteome R&D With $146M Deal for Alkahest

Alkahest, a company that analyzes blood proteins to develop therapies that address neurological disorders including Alzheimer’s disease, is set to be acquired by partner Grifols in a $146 million deal.Grifols (NASDAQ: GRFS) announced Tuesday that it is acquiring the shares of privately held Alkahest that it does not already own. Barcelona-based Grifols says the deal will help it discover new therapies for age-related diseases.Alkahest develops its therapeutic candidates by analyzing the proteom...
Tags: Deals, San Francisco, Trends, Startup, Neuroscience, Barcelona, Alzheimer's Disease, Novartis, Parkinson's Disease, Biotech, Life Sciences, Clinical Trials, San Carlos CA, Hologic, National blog main, Seattle blog main

Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally

Biofourmis, a digital therapeutics startup that employs wearable devices and data analytics to help treat patients, has raised $100 million to scale its offerings globally and develop new products that further blur the lines that once clearly separated drugs from medical devices.The new capital, a Series C round of funding, was led by SoftBank, a Japanese conglomerate whose investments include companies working in digital technology and healthcare.Biofourmis’s flagship technology, BiovitalsHF, ...
Tags: Deals, Boston, Softbank, Trends, Investing, Venture Capital, Fda, Novartis, Biotech, Sequoia Capital, Life Sciences, Pain Management, Medical Devices, Clinical Trials, Roche, MassMutual Ventures

Biotech Roundup: FDA Culpa, Tricida Trips, Freenome’s Funding & More

Among the casualties of the COVID-19 pandemic: the credibility of government agencies entrusted with protecting public health.The FDA this week granted emergency use authorization for convalescent plasma as a treatment for infection by the novel coronavirus. FDA Commissioner Stephen Hahn and Department of Health and Human Services Secretary Alez Azar both misrepresented the magnitude of benefit shown in the clinical data used to justify the decision. Public health officials have said more rigor...
Tags: Deals, Startups, Trends, Neuroscience, Acne, Harvard University, Alzheimer's Disease, Fda, National, Epilepsy, Novartis, Pfizer, Parkinson's Disease, Abbvie, Biotech, Medical Device

Freenome Tacks on $270M to Advance Blood Tests to Find Cancer Early

The ability to detect early signs of cancer in a patient’s blood could improve prognoses by helping doctors treat the disease before symptoms arise. Freenome, one of the companies racing to commercialize the first such screening test, on Wednesday announced it raised $270 million—money it plans to accelerate a clinical study of an experimental screening product designed to detect signs of colorectal cancer. The company also plans to explore which cancers it will target next.Investors have pumpe...
Tags: Startups, San Francisco, Trends, Venture Capital, Novartis, Andreessen Horowitz, Biotech, Financing, Bill Maris, Life Sciences, Liquid Biopsy, Roche, American Cancer Society, Sands Capital, Diagnostics, National blog main

Bio Roundup: A Telehealth Combo, FDA’s BCMA OK, Biogen’s Bet & More

The novel coronavirus has driven the pharmaceutical industry to upend its research priorities. Big Pharma companies are focusing on vaccine development and a slew of biotechs are testing compounds, previously intended for a wide range of indications, as potential COVID-19 treatments.This week saw another major development brought on by industry efforts to adjust to the new realities engendered by the pandemic, with the signing of an $18.5 billion merger in the digital health sector. How the tie...
Tags: Deals, Startups, Trends, Merck, Venture Capital, Fda, National, GlaxoSmithKline, Novartis, Abbvie, Biotech, Khosla Ventures, Life Sciences, Big Pharma, Sanofi, Valeant Pharmaceuticals

How to manage the future of work and reduce the employment gap

Despite recent surges in the stock market and the promising jobs numbers in the wake of the pandemic, the recovery has been quite uneven, hurting Black and Hispanic workers more than white employees, for example. The disparate effects of both the pandemic and nationwide protests and unrest reinforce the importance of addressing the widening national employment gap between the Haves and Have-Nots. The contrast between professional, educated, new-economy workers, and the rest of the workforce has ...
Tags: California, Opinion, Ebay, India, Sport, Soccer, Silicon Valley, Novartis, Mastercard, Modi, Macquarie Bank, Wipro, Mars Inc, Twitter Square, Westly Group, Josh Bersin

$29 billion biotech company Moderna just signed a big cloud deal with Amazon Web Services, even as the race for a COVID-19 vaccine accelerates

Biotech company Moderna on Wednesday announced that it has chosen Amazon Web Services as its preferred cloud partner. The company is seen as a leader in COVID-19 vaccine research, entering its third phase of clinical trials late July. Visit Business Insider's homepage for more stories. $29 billion biotech company Moderna announced a new partnership with Amazon Web Services on Wednesday that will see the cloud giant become its "preferred" cloud provider. The deal will also see Moderna tap AWS ...
Tags: Microsoft, Trends, United States, Aws, Novartis, Amazon Web Services, Moderna, Michael Yee, Bancel, COVID

Bio Roundup: Cerevel’s Shell, Thrive’s Rise, Drug Price Drama & More

The biotech IPO market is buzzing but Cerevel Therapeutics is showing that there’s more than one path to the public markets. This week the neuroscience drug developer reached a deal to merge with publicly traded Arya Sciences Acquisition Corp II.If you’ve never heard of Arya (NASDAQ: ARYBU), it’s a shell company that Perceptive Advisors formed specifically to serve as a vehicle to take a private company public. Cerevel is young, but it’s pretty far along. Bain Capital and Pfizer (NYSE: PFE) lau...
Tags: Deals, Sofinnova Partners, Cancer, Trends, Neuroscience, Anxiety, Schizophrenia, Autism, Alzheimer's Disease, Astrazeneca, National, GlaxoSmithKline, Novartis, Pfizer, Parkinson's Disease, Abbvie

Novartis Pays $75M to Get Hands on Sangamo’s Zinc Fingers for Drug R&D

Another biopharma has signed up to use Sangamo Therapeutics’ gene editing technology to develop therapies that can address disease by heightening or depressing a gene’s activity level.Sangamo on Thursday announced that Novartis (NYSE: NVS) had agreed to shell out $75 million up front to leverage the biotech’s genome regulation technology to treat certain neurodevelopmental conditions. Brisbane, CA-based Sangamo could earn up to $720 million in milestone payments, plus royalties on any products ...
Tags: Deals, San Francisco, Trends, Autism, Novartis, Biotech, Financing, Life Sciences, Licensing, AAV, Biogen, Gene Editing, Sangamo, Genome Editing, National blog main, National top stories

Omega Therapeutics Lands $85M to Tap Into “Control Room” of Biology

The promise of gene therapies and gene-editing drugs is a long-lasting treatment that’s potentially a cure. But making permanent genetic changes means any accompanying problems could be long-lasting as well, says Omega Therapeutics CEO Mahesh Karande.Omega is developing technology that takes a more nuanced approach to genomic medicine. Instead of fixing or replacing faulty genes, the company aims to harness the biological system that regulates them. If a gene is not properly translating DNA ins...
Tags: Deals, Startups, Trends, Investing, Mit, Novartis, Biotech, Life Sciences, Epigenetics, Genomic Medicine, Richard Young, Epizyme, National blog main, Boston blog main, Boston top stories, Whitehead Institute for Biomedical Research

Executive Leadership Expanded Ahead of First Potential U.S. Product Launch

NEW YORK, July 24, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq: MESO; ASX: MSB), global leader in cellular medicines for inflammatory diseases, today announced the appointment of Dagmar Rosa-Bjorkeson to the role of Chief Operating Officer (COO), based in New York. Ms Rosa-Bjorkeson’s responsibilities will include managing commercial operations, leading the business units, building out key strategic alliances, and overseeing product launches. She will be part of an expanded executive lead...
Tags: Europe, Business, Japan, New York, News, Australia, China, Singapore, United States, SEC, Novartis, Baxalta, Company, MSB, United States Food and Drug Administration FDA, Biosimilars

Brand Moves for Monday July 20

Twenty-one weeks ago, when the gravity of the situation became clear, we started daily reporting on how brands were dealing with the COVID-19 crisis. What’s now becoming clear is that the current climate is one of near-perpetual disruption. So we made the decision to keep on telling the stories of inspiring brand leadership and strategy amid the latest crises in an anxious world. Our goal remains the same: to provide an up-to-the-minute source of information, inspiration and insight on brand mo...
Tags: Google, Facebook, Adobe, India, Advertising, Disney, America, Spain, Barcelona, La Liga, Fifa, Real Madrid, Brookfield, Novartis, Hulu, Keanu Reeves

Indian drug mogul says Americans will pay too much for the Covid vaccine—and wants to change that

Adar Poonawalla is seizing on the Covid-19 fight to try to break down the policies protecting Big Pharma. Adar Poonawalla, chief executive officer of Serum Institute of India Ltd., says he’s in talks with Washington about clearing the way to sell some of his company’s earlier vaccine products in the U.S. market as low-cost generics. | Dhiraj Singh/Getty Images By SARAH WHEATON | Politico Adar Poonawalla may be the most important figure in the global vaccine race who isn’t working in a laborato...
Tags: Europe, Medicine, Microsoft, Congress, Washington, Life, India, Africa, Eu, West, Canada, Bill Gates, World Health Organization, Astrazeneca, Novartis, Bill

Bio Roundup: Moderna Publishes, Life Science Cash, AdComm Votes & More

If it seems like biotech investments have defied the financial headwinds of the pandemic, maybe it’s because they have. In the second quarter, 16 of the top 25 largest early-stage venture capital deals were investments in life science companies.The figures come from the National Venture Capital Association and financial research firm Pitchbook. This week they released their quarterly analysis of dealmaking, which shows that the tally of big biotech transactions tops the second quarter of 2019 w...
Tags: Deals, Startups, Cancer, Hiv, Trends, Investing, Merck, Infectious Diseases, Ovarian Cancer, National, Novartis, Vaccine, Immunotherapy, Biotech, Liver disease, Chemotherapy

Novartis Agrees To Pay $729M To Settle Kickback Lawsuit

The payments include $678 million related to speaker and promotional programs that took place between 2002-2011 and $51.25 million related to support for a charitable co-pay foundation. The lawsuit originated as a whistleblower suit in 2011.
Tags: Law, Novartis, Health Care / Medicine

Morning Docket: 07.02.20

* Novartis has settled a lawsuit which included allegations that the drugmaker gave money to doctors to induce them into prescribing certain medications. These claims would have spiced up the movie Love and Other Drugs... [NBC News] * An Ohio attorney has been arrested on federal bribery and extortion charges. [Toledo Blade] * Only seven law firm mergers and combinations have occurred during the second quarter of 2020 according to Altman Weil, likely due to the chilling effects of the ongoi...
Tags: New York, Law, Nbc News, Harvey Weinstein, Ohio, Novartis, ABA Journal, Altman Weil, Morning Docket, New York Attorney General, Massachusetts Lawyers Weekly, COVID-19, Love and Other Drugs

Engrail Therapeutics Launches With $32M to Develop New Neuro Drugs

Typically a new biotech assembles a group of investors that collectively puts in the money a fledgling company requires to develop or acquire potential therapies.Engrail Therapeutics, which emerged from stealth Thursday with $32 million in outside financing, landed its entire Series A funding from a sole source: Nan Fung Life Sciences, a subsidiary of Hong Kong property developer Nan Fung Group.The round, raised by an eight-person company with one preclinical asset, is a bet on Del Mar, CA-base...
Tags: Startups, Hong Kong, Funding, Trends, Neuroscience, Investing, Venture Capital, San Diego, Deal, Astrazeneca, Novartis, Allergan, Abbvie, Biotech, Financing, Life Sciences